Current treatment landscape for relapsed and/or refractory multiple myeloma

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

(2016) Teru Hideshima   Therapeutics and Clinical Risk Management

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

(2014) P. G. Richardson et al.   BLOOD

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

(2014) P. G. Richardson et al.   BLOOD

Targeted resequencing of 52 bone marrow failure genes in patients with aplastic anemia reveals an increased frequency of novel variants of unknown significance only in SLX4

(2014) L. C. Collopy et al.   HAEMATOLOGICA

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

(2013) M. Wang et al.   BLOOD

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

(2013) H. Ludwig et al.   BLOOD

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02

(2013) X. Leleu et al.   BLOOD

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

(2013) P. G. Richardson et al.   BLOOD

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

(2013) M. A. Dimopoulos et al.   BLOOD

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A

(2013) C. L. Eckhardt et al.   BLOOD

Autologous retransplantation for patients with recurrent multiple myeloma

(2013) Leopold Sellner et al.   CANCER

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

(2013) R. Niesvizky et al.   CLINICAL CANCER RESEARCH

Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients

(2013) J. Rosenblatt et al.   CLINICAL CANCER RESEARCH

Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database

(2013) Benjamin Honton et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

(2013) D. Siegel et al.   HAEMATOLOGICA

Current approaches for the treatment of multiple myeloma

(2013) Reiko Watanabe et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma

(2013) Jesús F. San-Miguel et al.   JOURNAL OF CLINICAL ONCOLOGY

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

(2013) A J Jakubowiak et al.   LEUKEMIA

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

(2013) J Schmidt et al.   LEUKEMIA

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

(2013) A Z Badros et al.   LEUKEMIA

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

Management of Double-Refractory Multiple Myeloma

(2013) Jason P. Meadows et al.   Current Hematologic Malignancy Reports

Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma

(2012) Emilie Lemieux et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

(2012) R. Vij et al.   BLOOD

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways

(2012) J. M. Burkhart et al.   BLOOD

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

(2012) M. A. Dimopoulos et al.   BLOOD

Proteasome inhibitors in multiple myeloma: 10 years later

(2012) P. Moreau et al.   BLOOD

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

(2012) S. Lentzsch et al.   BLOOD

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients

(2012) Jiri Minarik et al.   BRITISH JOURNAL OF HAEMATOLOGY

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

(2012) Ravi Vij et al.   BRITISH JOURNAL OF HAEMATOLOGY

Abstract 2607: The benefits of irreversibility: Infusion administration of carfilzomib results in potent proteasome inhibition and improved safety in animals

(2012) Jing Jiang et al.   CANCER RESEARCH

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

(2012) Laurent Garderet et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma

(2012) J R Berenson et al.   LEUKEMIA

European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses

(2012) H. Ludwig et al.   ONCOLOGIST

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

(2011) Victor H. Jimenez-Zepeda et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Phlebotomist's block

(2011) A. Possner   BLOOD

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

(2011) M. Q. Lacy et al.   BLOOD

Preclinical studies on targeted delivery of multiple IFN 2b to HLA-DR in diverse hematologic cancers

(2011) E. A. Rossi et al.   BLOOD

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

(2011) S. Madan et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

(2011) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats

(2011) J. Yang et al.   DRUG METABOLISM AND DISPOSITION

Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice

(2011) Francesco Trotta et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

(2011) Jacalyn Rosenblatt et al.   JOURNAL OF IMMUNOTHERAPY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Relapsed Multiple Myeloma

(2011) S. Lonial   Hematology-American Society of Hematology Education Program

Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A

(2010) Q. Shi et al.   BLOOD

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

(2010) M. Sant et al.   BLOOD

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study

(2010) Stephen A. Schey et al.   BRITISH JOURNAL OF HAEMATOLOGY

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations

(2010) B. Mohty et al.   HAEMATOLOGICA

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma

(2010) A Palumbo et al.   LEUKEMIA

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

(2010) H Avet-Loiseau et al.   LEUKEMIA

Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone

(2010) Hong Chang et al.   LEUKEMIA & LYMPHOMA

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

(2010) H. Ludwig et al.   ONCOLOGIST

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

(2009) F. Gay et al.   BLOOD

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

(2009) Edward A. Stadtmauer et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone

(2009) Maurizio Zangari et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

(2009) M A Dimopoulos et al.   LEUKEMIA

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma

(2008) A. Palumbo et al.   ANNALS OF ONCOLOGY

Thalidomide for treatment of multiple myeloma: 10 years later

(2008) A. Palumbo et al.   BLOOD

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

(2008) Joseph R. Mikhael et al.   BRITISH JOURNAL OF HAEMATOLOGY

Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy

(2008) Eric Vickrey et al.   CANCER

Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study

(2008) Asher Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

(2008) E Terpos et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma After One Prior Therapy

(2008) M. Hazarika et al.   ONCOLOGIST